RA Capital Management led a $144m Series B round in Outpace Bio.

RA Capital Management, a multi-stage investment manager, led a $144m Series B round in Outpace Bio, a cell therapy company. "Existing cell therapies have fallen short in treating solid tumors, offering limited and transient responses. We are proud to support Outpace’s revolutionary approach to cell therapy, leveraging their unique AI-driven protein design capabilities to solve the multiple obstacles preventing durable responses, with unmatched speed and success rates. The Outpace team is distinguished by their exceptional mechanism-driven science and commitment to deliver profound shifts in treatment outcomes for patients with solid tumors," Jake Simson, RA Capital Management Partner.